Hussein A. Tawbi - Concepedia

Author

Hussein A. Tawbi

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

D. Ashley, H A Tawbi, H Tawbi, H. A. Tawbi, H. Tawbi, H.A. Tawbi, H.A.-H. Tawbi, Hussain Tawbi, Hussein A Tawbi, Hussein A. Tawbi

514

Publications

24.9K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Melanoma Institute Australia Dana-Farber Cancer Institute The University of Sydney Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

About

Hussein A. Tawbi is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	50	9.2K
2	Health Sciences	10	10	1K
3	Public Health	2	2	862
4	Allergy	2	2	262
5	Biostatistics	1	1	47

Hussein A. Tawbi

118

Publications

22.1K

Citations

H-Index

Page 1

	Year	Citations
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients Vancheswaran Gopalakrishnan, Christine N. Spencer, Luigi Nezi, Science	2017	4.4K
B cells are associated with survival and immunotherapy response in sarcoma Florent Petitprez, Aurélien de Reyniès, Emily Z. Keung, Nature	2020	1.8K
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack, The Lancet Oncology OncologyPathologyAdvanced Soft-tissue SarcomaBone SarcomaImmune Checkpoint Inhibitor	2017	1.4K
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi, New England Journal of Medicine	2018	1.3K
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance Whijae Roh, Pei-Ling Chen, Alexandre Reuben, Science Translational Medicine T-regulatory CellImmunologyPathologyImmune Checkpoint BlockadeImmunotherapy	2017	902
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial Georgina V. Long, Uwe Trefzer, Michael A. Davies, The Lancet Oncology MedicineMelanomaPathologyVal600lys Braf-mutant MelanomaNeurology	2012	901
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial George D. Demetri, Margaret von Mehren, Robin L. Jones, Journal of Clinical Oncology	2015	809
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response Christine N. Spencer, Jennifer L. McQuade, Vancheswaran Gopalakrishnan, Science NutritionDysbiosisGut BacteriaImmunologyDietary Fibre	2021	804
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma Rodabe N. Amaria, Sangeetha M. Reddy, Hussein A. Tawbi, Nature Medicine MedicineMelanomaImmunologyTumor ImmunityImmune Checkpoint Inhibitor	2018	797
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy Lucie Heinzerling, Patrick A. Ott, F. Stephen Hodi, Journal for ImmunoTherapy of Cancer Heart FailureCancer ImmunosurveillanceAutoimmune DiseaseCheckpoint InhibitorsMedicine	2016	503

Page 1